Media coverage about Pieris Pharmaceuticals (NASDAQ:PIRS) has been trending somewhat positive on Monday, Accern reports. The research firm identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Pieris Pharmaceuticals earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.6160738333203 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news articles that may have effected Accern’s rankings:
- ETFs with exposure to Pieris Pharmaceuticals, Inc. : November 9, 2017 (finance.yahoo.com)
- Edited Transcript of PIRS earnings conference call or presentation 9-Nov-17 3:00pm GMT (finance.yahoo.com)
- HC Wainwright Reiterates Buy Rating for Pieris Pharmaceuticals, Inc. (PIRS) (americanbankingnews.com)
- Pieris Pharmaceuticals, Inc. (PIRS) Announces Quarterly Earnings Results (americanbankingnews.com)
- Pieris Pharmaceuticals Reports Financial Results for the Third Quarter Ended September 30, 2017, and Provides Corporate Update (finance.yahoo.com)
PIRS has been the subject of a number of research analyst reports. HC Wainwright set a $9.00 target price on shares of Pieris Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, October 18th. BidaskClub downgraded shares of Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 26th. Four analysts have rated the stock with a buy rating, Pieris Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $9.00.
Shares of Pieris Pharmaceuticals (PIRS) traded up $0.20 on Monday, hitting $5.45. 639,100 shares of the stock traded hands, compared to its average volume of 374,918. Pieris Pharmaceuticals has a 52 week low of $1.34 and a 52 week high of $6.58.
Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.16) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.05. Pieris Pharmaceuticals had a negative net margin of 321.83% and a negative return on equity of 180.85%. The company had revenue of $3.93 million for the quarter, compared to analyst estimates of $1.52 million. The business’s revenue for the quarter was up 400.3% on a year-over-year basis. research analysts forecast that Pieris Pharmaceuticals will post -0.83 earnings per share for the current year.
In other Pieris Pharmaceuticals news, Director James A. Geraghty purchased 10,000 shares of the company’s stock in a transaction dated Thursday, August 17th. The shares were bought at an average price of $4.82 per share, for a total transaction of $48,200.00. Following the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $48,200. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Allan Reine purchased 65,000 shares of the company’s stock in a transaction dated Thursday, August 17th. The shares were acquired at an average price of $4.82 per share, for a total transaction of $313,300.00. Following the purchase, the insider now owns 45,000 shares in the company, valued at $216,900. The disclosure for this purchase can be found here. Corporate insiders own 4.05% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Pieris Pharmaceuticals (PIRS) Earns Media Sentiment Score of 0.19” was first posted by Markets Daily and is owned by of Markets Daily. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.themarketsdaily.com/2017/11/14/pieris-pharmaceuticals-pirs-earns-media-sentiment-score-of-0-19.html.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.